Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Akebia Therapeutics Inc (NASDAQ: AKBA) was $1.65 for the day, up 6.45% from the previous closing price of $1.55. In other words, the price has increased by $6.45 from its previous closing price. On the day, 4.77 million shares were traded. AKBA stock price reached its highest trading level at $1.6797 during the session, while it also had its lowest trading level at $1.54.
Ratios:
Our analysis of AKBA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 01, 2025, initiated with a Buy rating and assigned the stock a target price of $6.
H.C. Wainwright Upgraded its Neutral to Buy on August 28, 2023, while the target price for the stock was maintained at $3.75.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 03 ’25 when Butler John P. sold 46,409 shares for $1.83 per share. The transaction valued at 84,928 led to the insider holds 2,557,921 shares of the business.
Burke Steven Keith sold 7,144 shares of AKBA for $13,074 on Mar 03 ’25. The SVP, Chief Medical Officer now owns 809,090 shares after completing the transaction at $1.83 per share. On Mar 03 ’25, another insider, Burke Steven Keith, who serves as the Officer of the company, bought 7,144 shares for $1.83 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 431031168 and an Enterprise Value of 526640256. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69. Its current Enterprise Value per Revenue stands at 3.288 whereas that against EBITDA is -60.519.
Stock Price History:
The Beta on a monthly basis for AKBA is 1.00, which has changed by 0.18705034 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $2.89, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is -16.49%, while the 200-Day Moving Average is calculated to be -2.31%.
Shares Statistics:
AKBA traded an average of 3.86M shares per day over the past three months and 4908930 shares per day over the past ten days. A total of 261.23M shares are outstanding, with a floating share count of 250.51M. Insiders hold about 4.10% of the company’s shares, while institutions hold 23.97% stake in the company. Shares short for AKBA as of 1743379200 were 17357699 with a Short Ratio of 4.49, compared to 1740700800 on 14879018. Therefore, it implies a Short% of Shares Outstanding of 17357699 and a Short% of Float of 6.7.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
